CSPG4 and neoplasm: Importantly, CSPG4 specific monoclonal antibodies and adoptive cell transfer therapies targeting CSPG4 have been effective in pre-clinical models by inhibition tumor growth and proliferation, making it a promising target for clinical application (18, 21–24).